Nonmelanoma skin cancer in solid organ transplant recipients: Update on epidemiology, risk factors, and management

Dermatologic Surgery

Volumn 38, Issue 10, 2012, Pages 1622-1630

  Tessari, Gianpaolo ^a   Girolomoni, Giampiero ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CAPECITABINE; CYCLOSPORIN; ETRETIN; FLUOROURACIL; GLUTATHIONE TRANSFERASE; IMIQUIMOD; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEIN P53; TACROLIMUS;

ACTINIC KERATOSIS; APOPTOSIS; AUSTRALIA; BLOOD CELL COUNT; CANCER INCIDENCE; CANCER RISK; CELL CYCLE ARREST; CRYOTHERAPY; DNA REPAIR; EUROPE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GRAFT RECIPIENT; HAND FOOT SYNDROME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ITALY; KERATINOCYTE; LIVER FUNCTION; MUCOSA INFLAMMATION; MYALGIA; NON MELANOMA SKIN CANCER; ORGAN TRANSPLANTATION; PAPILLOMAVIRUS INFECTION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RADIATION EXPOSURE; REVIEW; RISK REDUCTION; SKIN CARCINOGENESIS; SKIN COLOR; SKIN PIGMENTATION; SUN EXPOSURE; ULTRAVIOLET B RADIATION; VIRUS INFECTION;

EID: 84867054956     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2012.02520.x     Document Type: Review

References (84)

1. Carucci JA, Leffel DJ,. Basal cell carcinoma. In, Wolff K, Goldsmith LA, Gilchrest BA, Paller AS, Leffel DJ, editors. Fitzpatrick's Dermatology in General Medicine (7th ed). New York, Mc Graw Hill; 2007. pp. 1036-42.
2. Grossman D, Leffel DJ,. Squamous cell carcinoma. In, Wolff K, Goldsmith LA, Gilchrest BA, Paller AS, Leffel DJ, editors. Fitzpatrick's dermatology in general medicine (7th ed). New York, Mc Graw Hill; 2007. pp. 1028-36.
3. Duncan KO, Geisse JK, Leffel DJ,. Epithelial precancerous lesions. In, Wolff K, Goldsmith LA, Gilchrest BA, Paller AS, Leffel DJ, editors. Fitzpatrick's dermatology in general medicine (7th ed). New York, Mc Graw Hill; 2007. pp. 1007-27.
4. Wisgerhof HC, van der Boog PJ, de Fijter JW, Wolterbeek R, et al. Increased risk of squamous-cell carcinoma in simultaneous pancreas kidney transplant recipients compared with kidney transplant recipients. J Invest Dermatol 2009; 129: 2886-94.
5. Ulrich C, Kanitakis J, Stockfleth E, Euvrard S,. Skin cancer in organ transplant recipientsâwhere do we stand today? Am J Transplant 2008; 8: 2192-8.
6. Euvrard S, Kanitakis J, Claudy A,. Skin cancers after organ transplantation. N Engl J Med 2003; 348: 1681-91.
7. Bouwes Bavinck JN, Euvrard S, Naldi L, Nindl I, et al. Keratotic skin lesions and other risk factors are associated with skin cancer in organ-transplant recipients: a case-control study in The Netherlands, United Kingdom, Germany, France, and Italy. J Invest Dermatol 2007; 127: 1647-56.
8. Naldi L, Fortina AB, Lovati S, Barba A, et al. Risk of nonmelanoma skin cancer in Italian organ transplant recipients A registry-based study. Transplantation 2000; 70: 1479-84.
9. Bouwes Bavinck JN, Claas FH, Hardie DR, Green A, et al. Relation between HLA antigens and skin cancer in renal transplant recipients in Queensland, Australia. J Invest Dermatol 1997; 108: 708-11.
10. Bouwes Bavinck JN, Hardie DR, Green A, Cutmore S, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia A follow-up study. Transplantation 1996; 61: 715-21.
11. Tessari G, Naldi L, Boschiero L, Nacchia F, et al. Incidence and clinical predictors of a subsequent nonmelanoma skin cancer in solid organ transplant recipients with a first nonmelanoma skin cancer: a multicenter cohort study. Arch Dermatol 2010; 146: 294-9.
12. Moloney FJ, Comber H, Conlon PJ, Murphy GM,. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol 2006; 154: 790-1.
13. Stockfleth E, Kerl H,. Guidelines for the management of actinic keratoses. Eur J Dermatol 2006; 16: 599-606.
14. Euvrard S, Kanitakis J, Cochat P, Claudy A,. Skin cancers following paediatric organ transplantation. Dermatol Surg 2004; 30: 616-21.
15. Hofbauer GF, Bouwes Bavinck JN, Euvrard S,. Organ transplantation and skin cancer: basic problems and new perspectives. Exp Dermatol 2010; 19: 473-82.
16. Caforio AL, Fortina AB, Piaserico S, Alaibac M, et al. Skin cancer in heart transplant recipients: risk factor analysis and relevance of immunosuppressive therapy. Circulation 2000; 102: 222-7.
17. Terhorst D, Drecoll U, Stockfleth E, Ulrich C,. Organ transplant recipients and skin cancer: assessment of risk factors with focus on sun exposure. Br J Dermatol 2009; 161 (Suppl 3): 85-9.
18. Ulrich C, Jürgensen JS, Degen A, Hackethal M, et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol 2009; 161 (Suppl 3): 78-84.
19. Ho WL, Murphy GM,. Update on the pathogenesis of post-transplant skin cancer in renal transplant recipients. Br J Dermatol 2008; 158: 217-24.
20. Marcén R,. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs 2009; 69: 2227-43.
21. Fracasso ME, Barba A, Tessari G, Gasperini S, et al. Urinary mutagenic activity after different immunosuppressive protocols in renal transplant patients. Mutat Res 1993; 319: 279-83.
22. Jensen P, Hansen S, MÃller B, Leivestad T, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999; 40: 177-86.
23. Dantal J, Hourmant M, Cantarovich D, Giral M, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351: 623-8.
24. Euvrard S, Ulrich C, Lefrancois N,. Immunosuppressants and skin cancer in transplant patients: focus on rapamycin. Dermatol Surg 2004; 30: 628-33.
25. Duncan FJ, Wulff BC, Tober KL, Ferketich AK, et al. Clinically relevant immunosuppressants influence UVB-induced tumor size through effects on inflammation and angiogenesis. Am J Transplant 2007; 7: 2693-703.
26. Wulff BC, Kusewitt DF, VanBuskirk AM, Thomas-Ahner JM, et al. Sirolimus reduces the incidence and progression of UVB-induced skin cancer in SKH mice even with co-administration of cyclosporine A. J Invest Dermatol 2008; 128: 2467-73.
27. Salgo R, Gossmann J, Schöfer H, Kachel HG, et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant 2010; 10: 1385-93.
28. Monaco AP,. The role of mTOR inhibitors in the management of posttransplant malignancy. Transplantation 2009; 87: 157-63.
29. Rival-Tringali AL, Euvrard S, Decullier E, Claudy A, et al. Conversion from calcineurin inhibitors to sirolimus reduces vascularization and thickness of post-transplant cutaneous squamous cell carcinomas. Anticancer Res 2009; 29: 1927-32.
30. Tessmer CS, Magalhães LV, Keitel E, Valar C, et al. Conversion to sirolimus in renal transplant recipients with skin cancer. Transplantation 2006; 82: 1792-3.
31. Laing ME, Kay E, Conlon P, Murphy GM,. Genetic factors associated with skin cancer in renal transplant patients. Photodermatol Photoimmunol Photomed 2007; 23: 62-7.
32. Laing ME, Dicker P, Moloney FJ, Ho WL, et al. Association of methylenetetrahydrofolate reductase polymorphism and the risk of squamous cell carcinoma in renal transplant patients. Transplantation 2007; 84: 113-6.
33. Bastiaens MT, ter Huurne JA, Kielich C, Gruis NA, et al. Melanocortin-1 receptor gene variants determine the risk of nonmelanoma skin cancer independently of fair skin and red hair. Am J Hum Genet 2001; 68: 884-94.
34. Valverde P, Healy E, Jackson I, Rees JL, et al. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 1995; 11: 328-30.
35. Box NF, Duffy DL, Irving RE, Russell A, et al. Melanocortin-1 receptor genotype is a risk factor for basal and squamous cell carcinoma. J Invest Dermatol 2001; 116: 224-9.
36. Storey A, Thomas M, Kalita A, Harwood C, et al. Role of p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998; 393: 229-34.
37. Cairey-Remonnay S, Humbey O, Mougin C, Algros MP, et al. TP53 polymorphism of exon 4 at codon 72 in cutaneous squamous cell carcinoma and benign epithelial lesions of renal transplant recipients and immunocompetent individuals: lack of correlation with human papillomavirus status. J Invest Dermatol 2002; 118: 1026-31.
38. O'Connor DP, Kay EW, Leader M, Atkins GJ, et al. p53 codon 72 polymorphism and human papillomavirus associated skin cancer. J Clin Pathol 2001; 54: 539-42.
39. Lira MG, Provezza L, Malerba G, Naldi L, et al. Glutathione S-transferase and CYP1A1 gene polymorphisms and non-melanoma skin cancer risk in Italian transplanted patients. Exp Dermatol 2006; 15: 958-65.
40. O'Connor DP, Kay EW, Leader M, Murphy GM, et al. A high degree of chromosomal instability at 13q14 in cutaneous squamous cell carcinomas: indication for a role of a tumour suppressor gene other than RB. Mol Pathol 2001; 54: 165-9.
41. Alamartine E, Berthoux P, Mariat C, Cambazard F, et al. Interleukin-10 promoter polymorphisms and susceptibility to skin squamous cell carcinoma after renal transplantation. J Invest Dermatol 2003; 120: 99-103.
42. Turner DM, Williams DM, Sankaran D, Lazarus M, et al. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997; 24: 1-8.
43. Lira MG, Mazzola S, Tessari G, Malerba G, et al. Association of functional gene variants in the regulatory regions of COX-2 gene (PTGS2) with nonmelanoma skin cancer after organ transplantation. Br J Dermatol 2007; 157: 49-57.
44. Bouwes Bavinck JN, Vermeer BJ, van der Woude FJ, Vandenbroucke JP, et al. Relation between skin cancer and HLA antigens in renal-transplant recipients. N Engl J Med 1991; 325: 843-8.
45. Glover MT, Bodmer J, Bodmer W, Kennedy LJ, et al. HLA antigen frequencies in renal transplant recipients and non-immunosuppressed patients with non-melanoma skin cancer. Eur J Cancer 1993; 29: 520-4.
46. Orth G,. Human papillomaviruses associated with epidermodysplasia verruciformis in non-melanoma skin cancers: guilty or innocent? J Invest Dermatol 2005; 125 (1): xii-xiii.
47. Pfister H,. Chapter 8: human papillomavirus and skin cancer. J Natl Cancer Inst Monogr. 2003; 31: 52-6.
48. Berkhout RJ, Bouwes Bavinck JN, ter Schegget J,. Persistence of human papillomavirus DNA in benign and (pre)malignant skin lesions from renal transplant recipients. J Clin Microbiol 2000; 38: 2087-96.
49. Harwood CA, Surentheran T, McGregor JM, Spink PJ, et al. Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. J Med Virol 2000; 61: 289-97.
50. Mackintosh LJ, de Koning MN, Quint WG, Ter Schegget J, et al. Presence of beta human papillomaviruses in nonmelanoma skin cancer from organ transplant recipients and immunocompetent patients in the West of Scotland. Br J Dermatol 2009; 161: 56-62.
51. Bouwes Bavinck JN, Neale RE, Abeni D, Euvrard S, et al. Multicenter study of the association between betapapillomavirus infection and cutaneous squamous cell carcinoma. Cancer Res 2010; 70: 9777-86.
52. Purdie KJ, Surentheran T, Sterling JC, Bell L, et al. Human papillomavirus gene expression in cutaneous squamous cell carcinomas from immunosuppressed and immunocompetent individuals. J Invest Dermatol 2005; 125: 98-107.
53. Jackson S, Storey A,. E6 proteins from diverse cutaneous HPV types inhibit apoptosis in response to UV damage. Oncogene 2000; 19: 592-8.
54. Underbrink MP, Howie HL, Bedard KM, Koop JI, et al. E6 proteins from multiple human betapapillomavirus types degrade Bak and protect keratinocytes from apoptosis after UVB irradiation. J Virol 2008; 82: 10408-17.
55. Iftner T, Elbel M, Schopp B, Hiller T, et al. Interference of papillomavirus E6 protein with single-strand break repair by interaction with XRCC1. EMBO J 2002; 21: 4741-8.
56. Giampieri S, Storey A,. Repair of UV-induced thymine dimers is compromised in cells expressing the E6 protein from human papillomaviruses types 5 and 18. Br J Cancer 2004; 90: 2203-9.
57. Akgül B, Cooke JC, Storey A,. HPV-associated skin disease. J Pathol 2006; 208: 165-75.
58. Akgül B, García-Escudero R, Ghali L, Pfister HJ, et al. The E7 protein of cutaneous human papillomavirus type 8 causes invasion of human keratinocytes into the dermis in organotypic cultures of skin. Cancer Res 2005; 65: 2216-23.
59. Boxman IL, Russell A, Mulder LH, Bavinck JN, et al. Case-control study in a subtropical Australian population to assess the relation between non-melanoma skin cancer and epidermodysplasia verruciformis human papillomavirus DNA in plucked eyebrow hairs The Nambour Skin Cancer Prevention Study Group. Int J Cancer 2000; 86: 118-21.
60. Boxman IL, Russell A, Mulder LH, Bavinck JN, et al. Association between epidermodysplasia verruciformis-associated human papillomavirus DNA in plucked eyebrow hair and solar keratoses. J Invest Dermatol 2001; 117: 1108-12.
61. Forslund O, Iftner T, Andersson K, Lindelof B, et al. Cutaneous human papillomaviruses found in sun-exposed skin: beta-papillomavirus species 2 predominates in squamous cell carcinoma. J Infect Dis 2007; 196: 876-83.
62. Proby CM, Harwood CA, Neale RE, Green AC, et al. A case-control study of betapapillomavirus infection and cutaneous squamous cell carcinoma in organ transplant recipients. Am J Transplant 2011; 11: 1498-508.
63. Stasko T, Brown MD, Carucci JA, Euvrard S, et al. Guidelines for the management of squamous cell carcinoma in organ transplant recipients. Dermatol Surg 2004; 30: 642-50.
64. O'Reilly Zwald F, Brown M,. Skin cancer in solid organ transplant recipients: advances in therapy and management Part II. Management of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 2011; 65: 263-79.
65. Brown VL, Atkins CL, Ghali L, Cerio R, et al. Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double-blind, placebo-controlled trial. Arch Dermatol 2005; 141: 985-93.
66. Kovach BT, Stasko T,. Use of topical immunomodulators in organ transplant recipients. Dermatol Ther 2005; 18: 19-27.
67. Piaserico S, Belloni Fortina A, Rigotti P, Rossi B, et al. Topical photodynamic therapy of actinic keratoses in renal transplant recipients. Transplant Proc 2007; 39: 1847-50.
68. de Graaf YG, Kennedy C, Wolterbeek R, Collen AF, et al. Photodynamic therapy does not prevent cutaneous squamous-cell carcinoma in organ-transplant recipients: results of a randomized-controlled trial. J Invest Dermatol 2006; 126: 569-74.
69. Traywick C, O'Reilly FM,. Management of skin cancer in solid organ transplant recipients. Dermatol Ther 2005; 18: 12-8.
70. Miller SJ, Alam M, Andersen J, et al. Basal cell and squamous cell skin cancers. J Natl Compr Canc Netw 2010; 8: 836-64.
71. Civantos FJ, Zitsch RP, Schuller DE, Agrawal A, et al. Sentinel lymph node biopsy accurately stages the regional lymph nodes for T1-T2 oral squamous cell carcinomas: results of a prospective multi-institutional trial. J Clin Oncol 2010; 28: 1395-400.
72. Kwon S, Dong ZM, Wu PC,. Sentinel lymph node biopsy for high-risk cutaneous squamous cell carcinoma: clinical experience and review of literature. World J Surg Oncol 2011; 9: 80.
73. Ross AS, Schmults CD,. Sentinel lymph node biopsy in cutaneous squamous cell carcinoma: a systematic review of the English literature. Dermatol Surg 2006; 32: 1309-21.
74. George R, Weightman W, Russ GR, Bannister KM, et al. Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients. Australas J Dermatol 2002; 43: 269-73.
75. Kovach BT, Sams HH, Stasko T,. Systemic strategies for chemoprevention of skin cancers in transplant recipients. Clin Transplant 2005; 19: 726-34.
76. De Graaf YG, Euvrard S, Bouwes Bavinck JN,. Systemic and topical retinoids in the management of skin cancer in organ transplant recipients. Dermatol Surg 2004; 30: 656-61.
77. Jirakulaporn T, Endrizzi B, Lindgren B, Mathew J, et al. Capecitabine for skin cancer prevention in solid organ transplant recipients. Clin Transplant 2011; 25: 541-8.
78. Endrizzi BT, Lee PK,. Management of carcinoma of the skin in solid organ transplant recipients with oral capecitabine. Dermatol Surg 2009; 35: 1567-72.
79. Otley CC, Maragh SL,. Reduction of immunosuppression for transplant-associated skin cancer: rationale and evidence of efficacy. Dermatol Surg 2005; 31: 163-8.
80. Haagsma EB, Hagens VE, Schaapveld M, et al. Increased cancer risk after liver transplantation: a population-based study. J Hepatol 2001; 34: 84-91.
81. Herrero JI, España A, Quiroga J, Sangro B, et al. Nonmelanoma skin cancer after liver transplantation Study of risk factors. Liver Transpl 2005; 11: 1100-6.
82. Lindelöf B, Sigurgeirsson B, Gäbel H, Stern RS,. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 2000; 143: 513-9.
83. Liddington M, Richardson AJ, Higgins RM, Endre ZH, et al. Skin cancer in renal transplant recipients. Br J Surg 1989; 76: 1002-5.
84. Euvrard S, Kanitakis J, Decullier E, Butnaru AC, et al. Subsequent skin cancers in kidney and heart transplant recipients after the first squamous cell carcinoma. Transplantation 2006; 81: 1093-100.